Kozicka Karolina, Łukasik Adriana, Pastuszczak Maciej, Wojas-Pelc Anna
Department of Dermatology, Jagiellonian University, Collegium Medicum, Cracow, Poland.
Pol Merkur Lekarski. 2019 Feb 28;46(272):80-83.
Androgenetic alopecia (AGA in men/female pattern hair loss FPHL in women) has been associated with the most frequent culprit of hair loss concerning both men and women. It may be viewed as chronic, progressive, non scarring type of hair loss. The main factor in its pathophysiological mechanism plays genetic susceptibility to androgens of certain individuals. Increased level of androgens shown to be the cause in men, whereas in women this level may be elevated or normal. For the management of the condition topical treatment with minoxidil has been approved, as well as orally administered finasteryd, spironolakton or dutasteride.
The main objective of this research project was to study the patients with AGA in terms of gender, age, prescribed treatment and hormone dysfunctions.
The analyzed population consisted of 104 patients treated in dermatology department in Cracow in three years period (2015-2018) for AGA. Initially, demographic characteristics and treatment were tested. The next step of the analysis was the comparison of groups according to gender and, what is more among women according to age (up to 45 and >45 years of age). Statistical analysis was performed with U Mann-Whitney and Chi square Pearsons tests.
The majority of patients participating in the study were women (87,5%). The average age of the study population was 45,5±15,5 years of age. The most frequently ordered medicine was minoxidil 5% solution (82,2% of patients), besides polytherapy of two medicines were applied in 45,8% of patients. In the study group hypothyroidism was observed in 10.6% of patients. The examined group of women were older than men (48.3 vs. 25.8 years; p<0.0001). Male patients were more often ordered systemic treatment (52.9 vs.15,4%; p=0.0012), whereas topical treatment was more often applied to women (94.5 vs. 69.2; p=0.0024). Women usually were ordered more than one medicine in contrast to men (44.0 vs. 15.4%; p=0.0495). Therefore no significant difference between women up to 45 and >45 years of age was observed.
Statistically significant occurrence of hypothyroidism was observed. Therefore this connection requires further studies. Other endocrinological dysfunctions like acne, hirsutism or menstrual disorder were relatively rare.
雄激素性脱发(男性为AGA,女性为女性型脱发FPHL)是男女脱发最常见的原因。它可被视为一种慢性、进行性、非瘢痕性脱发。其病理生理机制的主要因素是某些个体对雄激素的遗传易感性。雄激素水平升高在男性中被证明是病因,而在女性中该水平可能升高或正常。对于该病症的治疗,外用米诺地尔已获批准,口服非那雄胺、螺内酯或度他雄胺也可使用。
本研究项目的主要目的是从性别、年龄、规定治疗方法和激素功能障碍方面研究雄激素性脱发患者。
分析的人群包括在克拉科夫皮肤科三年期间(2015 - 2018年)接受雄激素性脱发治疗的104例患者。最初,对人口统计学特征和治疗方法进行了测试。分析的下一步是根据性别对组进行比较,并且在女性中还根据年龄(45岁及以下和45岁以上)进行比较。使用曼 - 惠特尼U检验和卡方皮尔逊检验进行统计分析。
参与研究的大多数患者为女性(87.5%)。研究人群的平均年龄为45.5±15.5岁。最常开具的药物是5%米诺地尔溶液(82.2%的患者),此外45.8%的患者采用了两种药物的联合治疗。在研究组中,10.6%的患者观察到甲状腺功能减退。被检查的女性组比男性组年龄大(48.3岁对25.8岁;p<0.0001)。男性患者更常接受全身治疗(52.9%对15.4%;p = 0.0012),而女性更常采用局部治疗(94.5%对69.2%;p = 0.0024)。与男性相比,女性通常开具不止一种药物(44.0%对15.4%;p = 0.0495)。因此,45岁及以下和45岁以上的女性之间未观察到显著差异。
观察到甲状腺功能减退在统计学上有显著发生率。因此这种关联需要进一步研究。其他内分泌功能障碍如痤疮、多毛症或月经紊乱相对较少见。